Bellicum Pharmaceuticals: Immuntherapie auf Profitsuche

eher bloß ?Gezocke?.  Schade auch?  

 

Baker Bros. Advisors LP hält 19,99% Anteil

https://ir.bellicum.com/node/11256/html

 

 

Baker Bros. Advisors ...

Ein Hedgefunds https://whalewisdom.com/filer/baker-bros-advisors-llc
mit 2 Kunden und $25,7Mrd AUM

Bellicum hat ja seit 6.April 45 Tage Zeit wieder die Nasdaq-Kriterien zu erfüllen. (Über $1)
https://www.marketscreener.com/quote/stock/...isting-Rule-o-43465367/

Was soll das werden ? Übernahme ?
Ab wieviel % muss es ein Pflichtangebot an die Aktionäre geben.. 30% ?

 

96 Mio. ist aber ein irres Handels-Volumen heute, wenn man bedenkt, dass es nur 8,xMio Bellicum-Aktien gibt !
https://www.nasdaq.com/market-activity/stocks/blcm
 

 

Weiß jemand was hier los ist?

Die Baker Bros. haben ihre vielen Aktien offenbar benutzt um sie an Shorter zu verleihen. Jedenfalls spricht das der Kurs.

Die 45 Tage sind vorbei. (Schon seit Tagen)
Aber von Bellicum kommt keine News zu dem Thema
https://ir.bellicum.com/
 

https://quantisnow.com/feed    aus der Liste genmmen  

ab Montag nicht mehr an der Nasdaq gelistet.
Kriterien nicht erfüllt.
Jetzt nur noch OTC-QX- Handel
BLCM

Mit einem Resplit hätten sie das Problem eigentlich lösen können.. :(

https://www.streetinsider.com/SEC+Filings/...%3A+May+30/21735958.html
"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed by Bellicum Pharmaceuticals, Inc. (the ?Company?), pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the ?SEC?) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (?Nasdaq?) that the Company?s stockholders? equity as reported in the Company?s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (?Rule 5550(b)(1)?). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1).

The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company?s right to request an appeal, trading of the Company?s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company?s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination.

The Company anticipates that effective June 2, 2023, the Company?s common stock will commence trading on the OTCQX marketplace under the symbol ?BLCM.? Quotes and related Company information will be available at www.otcmarkets.com..."